ITMI20061854A1 - BEVERAGE SUITED TO SLOW DOWN CELL DEGENERATION THAT ACCOMPANIES AGING - Google Patents
BEVERAGE SUITED TO SLOW DOWN CELL DEGENERATION THAT ACCOMPANIES AGING Download PDFInfo
- Publication number
- ITMI20061854A1 ITMI20061854A1 IT001854A ITMI20061854A ITMI20061854A1 IT MI20061854 A1 ITMI20061854 A1 IT MI20061854A1 IT 001854 A IT001854 A IT 001854A IT MI20061854 A ITMI20061854 A IT MI20061854A IT MI20061854 A1 ITMI20061854 A1 IT MI20061854A1
- Authority
- IT
- Italy
- Prior art keywords
- beverage according
- carnosine
- epigallocatechin gallate
- beverage
- folic acid
- Prior art date
Links
- 235000013361 beverage Nutrition 0.000 title claims description 31
- 230000032683 aging Effects 0.000 title claims description 18
- 230000007850 degeneration Effects 0.000 title claims description 7
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 19
- 108010087806 Carnosine Proteins 0.000 claims description 17
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 17
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 17
- 239000011777 magnesium Substances 0.000 claims description 17
- 239000011701 zinc Substances 0.000 claims description 17
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 16
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 16
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- 229940028434 carnosine 100 mg Drugs 0.000 claims description 9
- 229940063755 folic acid 0.1 mg Drugs 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 230000001413 cellular effect Effects 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 235000008160 pyridoxine Nutrition 0.000 claims description 6
- 239000011677 pyridoxine Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- 229940098524 pyridoxine 1 mg Drugs 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 239000001755 magnesium gluconate Substances 0.000 claims description 3
- 229960003035 magnesium gluconate Drugs 0.000 claims description 3
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 3
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 3
- 239000011746 zinc citrate Substances 0.000 claims description 3
- 235000006076 zinc citrate Nutrition 0.000 claims description 3
- 229940068475 zinc citrate Drugs 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000000203 mixture Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 6
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 4
- 229940114124 ferulic acid Drugs 0.000 description 4
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 4
- 235000001785 ferulic acid Nutrition 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 4
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013065 commercial product Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 3
- 229940050410 gluconate Drugs 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MFCMBWRHOUCXEZ-CAHLUQPWSA-N 3-aminopropyl [(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-yl] hydrogen phosphate Chemical compound NCCCOP(O)(=O)OC1=C(O)[C@@H]([C@@H](O)CO)OC1=O MFCMBWRHOUCXEZ-CAHLUQPWSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 208000026005 Central nervous system vascular disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000016761 Haem oxygenases Human genes 0.000 description 1
- 108050006318 Haem oxygenases Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007253 cellular alteration Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Tea And Coffee (AREA)
Description
7709PTIT Notarbartoio & Gervasi S.p.A. 7709PTIT Notarbartoio & Gervasi S.p.A.
Descrizione dell'invenzione industriale dal titolo : Description of the industrial invention entitled:
“Bevanda atta a rallentare la degenerazione cellulare che accompagna “Drink designed to slow down the accompanying cellular degeneration
l'invecchiamento” aging "
a nome di: GENALTA S.r.l. in the name of: GENALTA S.r.l.
con sede in; SESTO FIORENTINO (FI) ®ϋβ 4 0 0 f 8 5 4 Inventori designati: BERNASCONI Sara, BERTINI Ivano, LUCCIOLA based in; SESTO FIORENTINO (FI) ®ϋβ 4 0 0 f 8 5 4 Designated inventors: BERNASCONI Sara, BERTINI Ivano, LUCCIOLA
Isidoro, LUCHINAT Claudio, QUATTRONE Alessandro, SCAPAGNINI Isidoro, LUCHINAT Claudio, QUATTRONE Alessandro, SCAPAGNINI
Giovanni John
CAMPO DELL’INVENZIONE FIELD OF THE INVENTION
La presente invenzione si riferisce al campo generale della prevenzione The present invention relates to the general field of prevention
delle patologie croniche colfegate all'invecchiamento, tra cui i disordini chronic diseases linked to aging, including disorders
del sistema nervoso centrale e le patologie cardiovascolari. of the central nervous system and cardiovascular diseases.
In particolare, l’invenzione riguarda una bevanda la cui formulazione In particular, the invention relates to a drink whose formulation
contiene una miscela di composti in grado di attivare in maniera specifica it contains a mixture of compounds capable of activating in a specific way
una famiglia di geni e proteine ad azione antiossidante ed a family of genes and proteins with antioxidant action ed
antiinfiammatoria, nota con il termine generico dì vitageni. anti-inflammatory, known by the generic term of vitagens.
Attraverso tale azione la bevanda oggetto della presente domanda di Through this action, the beverage that is the subject of this application for
brevetto è efficace nel potenziare la vitalità cellulare, tissutale ed patent is effective in enhancing cellular, tissue and vitality
organismica ed in particolare risulta efficace nel proteggere le cellule del organismic and in particular it is effective in protecting the cells of the
sistema nervoso centrale e periferico e le cellule endoteliali dal central and peripheral nervous system and endothelial cells from the
deterioramento, dalla morte legata a processi degenerativi e deterioration, from death linked to degenerative processes e
dall’invecchiamento in generale. from aging in general.
STATO DELL’ARTE STATE OF THE ART
La teoria più moderna che tenta di spiegare il fenomeno biologico The most modern theory that attempts to explain the biological phenomenon
dell’invecchiamento, ritiene che per una serie di meccanismi in parte endogeni (che si sviluppano all’interno deH’organismo) ed in parte esogeni (ambientali), si verifichino nel corso della vita molteplici alterazioni cellulari (ad esempio, nelle membrana delle cellule, negli enzimi, nelle proteine, nei DNA e nelt’RNA). Queste alterazioni porterebbero rapidamente all'invecchiamento ed alla morte se il nostro organismo non possedesse importanti meccanismi di difesa, la cui efficienza è sotto controllo genetico. of aging, believes that due to a series of mechanisms partly endogenous (which develop inside the organism) and partly exogenous (environmental), multiple cellular alterations occur over the course of life (for example, in the cell membranes , enzymes, proteins, DNA and RNA). These alterations would rapidly lead to aging and death if our organism did not possess important defense mechanisms, whose efficiency is under genetic control.
Questi geni che si attivano per potenziare la vitalità della cellula, e quindi dei tessuti e dell'intero organismo sono stati recentemente battezzati con il termine di vitageni, i geni della vita, i geni della giovinezza (Calabrese V, Butterfield DA, Scapagnini G; Stella AM, Maines MD (2006) Antiredox Redox Signal. 8 (3-4): 444-477). These genes that are activated to enhance the vitality of the cell, and therefore of the tissues and of the whole organism, have recently been baptized with the term of vitagens, the genes of life, the genes of youth (Calabrese V, Butterfield DA, Scapagnini G; Stella AM, Maines MD (2006) Antiredox Redox Signal. 8 (3-4): 444-477).
Alla categoria dei vitageni appartengono geni ìnducibili codificanti per proteine ad azione antiossidante come la Superossidodismutasi-2 (SOD-2) o l’Emeossigenasi-1 (HO-1), ad azione antitumorale come gli enzimi detossificanti di tipo 2, o ad attività di ristrutturazione delie proteine danneggiate come le Heat Shock Proteina (Calabrese V., Scapagnini G., Colombrita C., Ravagna A., Pennisi G., Giuffrida, Stella AM, Galli F, Butterfield DA (2003) Amino Acids 25 (3-4): 337-344) To the category of vitagens belong inducible genes coding for proteins with antioxidant action such as Superoxide dismutase-2 (SOD-2) or Emeoxygenase-1 (HO-1), with antitumor action such as type 2 detoxifying enzymes, or with antioxidant activity. restructuring of damaged proteins such as Heat Shock Proteins (Calabrese V., Scapagnini G., Colombrita C., Ravagna A., Pennisi G., Giuffrida, Stella AM, Galli F, Butterfield DA (2003) Amino Acids 25 (3-4 ): 337-344)
Mediante la costante attivazione di questo complesso macchinario genetico è così possibile la riparazione di tutti i danni mano a mano che essi si verificano. Through the constant activation of this complex genetic machinery it is thus possible to repair all the damages as they occur.
Numerosi studi epidemiologici hanno evidenziato negli ultimi anni, una correlazione diretta tra la tipologia di dieta e l’incidenza e la severità delle 7709PTIT Notarbartolo & Gervasi S.p.A.f/ Numerous epidemiological studies have shown in recent years a direct correlation between the type of diet and the incidence and severity of 7709PTIT Notarbartolo & Gervasi S.p.A.f /
malattie croniche legate all'invecchiamento, dando fondamento all<'>idea che i composti chimici presenti nel cibo, modulando l’attività di geni e proteine, possano influenzare in un individuo l’equilibrio tra stato di salute e stato di malattia e condizionare così la qualità del suo invecchiamento, lo stato di benessere e l’instaurarsi di patologie degenerative. Le molecole chimiche contenute nei cibi sono infatti in grado di agire sul genoma, sia direttamente che indirettamente, ed alterare l’espressione genica. chronic diseases linked to aging, giving basis to the idea that the chemical compounds present in food, by modulating the activity of genes and proteins, can influence in an individual the balance between state of health and state of disease and thus condition the quality of its aging, the state of well-being and the onset of degenerative pathologies. The chemical molecules contained in foods are in fact able to act on the genome, both directly and indirectly, and alter gene expression.
Negli ultimi anni, numerosi studi sperimentali hanno dimostrato la capacità di alcune di queste sostanze di attivare geni appartenenti al gruppo dei vitageni, aprendo in tal modo una nuova prospettiva all’approccio nutrizionale quale potente presidio di prevenzione e cura dì tutto un ventaglio di patologie croniche legate all'invecchiamento. In recent years, numerous experimental studies have demonstrated the ability of some of these substances to activate genes belonging to the group of vitagens, thus opening a new perspective to the nutritional approach as a powerful safeguard for the prevention and treatment of a whole range of chronic diseases. related to aging.
L'allungamento della aspettativa di vita e l’aumento della popolazione anziana nei paesi industrializzati nell’ultimo secolo ha portato in primo piano la necessità di migliorare le condizioni di salute nella terza età, A tutt’oggi non è stato sviluppato alcun prodotto avente un’azione preventiva delle degenerazioni cellulari dovute all’invecchiamento, senza tuttavia avere le caratteristiche di un farmaco. The lengthening of life expectancy and the increase in the elderly population in industrialized countries in the last century has brought to the fore the need to improve health conditions in old age. preventive action of cellular degeneration due to aging, without however having the characteristics of a drug.
Sono note bevande contenenti sostanze che conferiscono loro proprietà aggiuntive alla mera capacità di idratazione. Beverages containing substances are known which give them additional properties to the mere capacity of hydration.
Ad esempio, sono largamente diffusi in commercio integratori salini, utilizzati dagli sportivi per facilitare la reidratazione ed evitare la iponatremia durante lo sforzo fisico. Spesso queste bevande contengono anche zuccheri a rapido assorbimento con lo scopo dì fornire una fonte For example, saline supplements are widely used on the market, used by athletes to facilitate rehydration and avoid hyponatremia during physical exertion. Often these drinks also contain rapidly absorbed sugars for the purpose of providing a source
energetica subito disponibile. energy immediately available.
Inoltre, sono note anche bevande, che agiscono da integratori di vitamine e sali minerali, In addition, drinks are also known, which act as supplements of vitamins and mineral salts,
SOMMARIO DELL'INVENZIONE SUMMARY OF THE INVENTION
La Richiedente ha ora messo a punto una bevanda che si presenta come una normale acqua, fruibile da chiunque e senza limitazioni di quantità né particolari controindicazioni, avente un effetto preventivo, nel lungo termine di una assunzione sistematica, nel rallentare e parzialmente impedire le degenerazioni cellulari dovute all’invecchiamento. The Applicant has now developed a drink that looks like normal water, usable by anyone and without quantity limitations or particular contraindications, having a preventive effect, in the long term of a systematic intake, in slowing down and partially preventing cellular degeneration. due to aging.
Tale bevanda si basa su di una formulazione originale che comprende molecole appartenenti alla famiglia dei polifenoli vegetali (ECCG, acido ferulico), dipeptidi (carnosina) e minerali (zinco e magnesio) che, disciolti in soluzione acquosa, in maniera congiunta e sinergica e mediante differenti meccanismi d’azione, attivano specificamente il sistema dei vitageni e, così facendo aumentano le difese cellulari. This drink is based on an original formulation that includes molecules belonging to the family of vegetable polyphenols (ECCG, ferulic acid), dipeptides (carnosine) and minerals (zinc and magnesium) which, dissolved in aqueous solution, jointly and synergistically and through different mechanisms of action specifically activate the vitagen system and, in so doing, increase cellular defenses.
DESCRIZIONE DETTAGLIATA DELL’INVENZIONE DETAILED DESCRIPTION OF THE INVENTION
Oggetto della presente invenzione è una bevanda costituita da una soluzione acquosa comprendente epigallocatechina gallato, L-carnosina, acido folico, Zn<2+>e Mg<2+>. Tale bevanda si presenta come una normale acqua, essendo sostanzialmente insapore, incolore ed inodore. The object of the present invention is a drink consisting of an aqueous solution comprising epigallocatechin gallate, L-carnosine, folic acid, Zn <2+> and Mg <2+>. This drink looks like normal water, being substantially tasteless, colorless and odorless.
La Richiedente ha trovato che quando la bevanda della presente invenzione viene utilizzata in sostituzione di una normale acqua minerale, preferibilmente in quantità pari a 2 litri al giorno, si osserva un effetto preventivo dei processi degenerativi indotti dall'invecchiamento. Tale effetto preventivo, inoltre, risulta più efficace se la somministrazione 7709PTIT Notarbartolo & Gervasi S.p.A. The Applicant has found that when the beverage of the present invention is used in substitution of a normal mineral water, preferably in a quantity equal to 2 liters per day, a preventive effect of the degenerative processes induced by aging is observed. Furthermore, this preventive effect is more effective if the administration 7709PTIT Notarbartolo & Gervasi S.p.A.
viene iniziata prima che il processo di invecchiamento inizi. it is started before the aging process begins.
Pertanto, l'utilizzo della bevanda della presente invenzione è indicato non solo ad individui anziani ma in qualsiasi fascia di età. Therefore, the use of the beverage of the present invention is indicated not only for elderly individuals but in any age group.
Preferibilmente i suddetti componenti sono presenti in detta bevanda nelle seguenti concentrazioni; Preferably the aforesaid components are present in said beverage in the following concentrations;
Epìgallocatechina gallato 50-70 mg/L Epìgallocatechin gallate 50-70 mg / L
L-carnosina 90-110 mg/L L-carnosine 90-110 mg / L
acido foìico 0.1-0.15 mg/L phylic acid 0.1-0.15 mg / L
Zn<2+>3-10 mg/L Zn <2+> 3-10 mg / L
Mg<2+>80-120 mg/L Mg <2+> 80-120 mg / L
Preferibilmente, lo Zn<2+>è presente nella bevanda della presente invenzione come zinco citrato. Preferably, Zn <2+> is present in the beverage of the present invention as zinc citrate.
Preferibilmente, il Mg<2+>è presente nella bevanda della presente invenzione come magnesio gluconato. Preferably, the Mg <2+> is present in the beverage of the present invention as magnesium gluconate.
Secondo un’applicazione particolarmente preferita, la bevanda della presente invenzione contiene, oltre ai suddetti componenti, anche piridossina, preferibilmente in forma di idrocloruro. According to a particularly preferred application, the beverage of the present invention contains, in addition to the aforementioned components, also pyridoxine, preferably in the form of hydrochloride.
Preferibilmente, la piridossina è presente nella presente bevanda ad una concentrazione compresa tra 1,0 e 1.5 mg/L, ancor più preferibilmente pari a 1 mg/L. Preferably, pyridoxine is present in the present drink at a concentration ranging from 1.0 to 1.5 mg / L, even more preferably equal to 1 mg / L.
Una formulazione particolarmente preferita della bevanda della presente invenzione comprende; A particularly preferred formulation of the beverage of the present invention comprises;
Epìgallocatechina gallato 60 mg/L Epìgallocatechin gallate 60 mg / L
L-carnosina 100 mg/L L-carnosine 100 mg / L
acìdo folico 0.1 mg/L folic acid 0.1 mg / L
7709PTIT Notarbarìolo & Gervasi S.p.A. i 7709PTIT Notarbarìolo & Gervasi S.p.A. the
Zn<2+>4 mg/L Zn <2+> 4 mg / L
Mg<2+>100 mg/L Mg <2+> 100 mg / L
Nonostante alcuni dei suddetti componenti siano molto sensibili all'ossidazione e quindi instabili in ambiente acquoso, la formulazione della presente invenzione risulta stabile per almeno 8-12 mesi. Although some of the above components are very sensitive to oxidation and therefore unstable in an aqueous environment, the formulation of the present invention is stable for at least 8-12 months.
La bevanda secondo l’invenzione può inoltre comprendere acido ascorbico, preferibilmente in concentrazione compresa tra 60 e 90 mg/L. Secondo un’ulteriore forma di realizzazione, la bevanda della presente invenzione può contenere componenti che la rendono specificamente destinata a consumatori uomini o donne, in vista delie diverse e specifiche cause che provocano l’invecchiamento nei due casi. The drink according to the invention can also comprise ascorbic acid, preferably in a concentration between 60 and 90 mg / L. According to a further embodiment, the drink of the present invention can contain components that make it specifically intended for male or female consumers, in view of the different and specific causes that cause aging in the two cases.
Pertanto, qualora Sa bevanda della presente invenzione sia destinata ad essere utilizzata da una popolazione femminile essa contiene preferibilmente, oltre ai suddetti componenti, anche biotina, preferibilmente in concentrazione compresa tra 0,07 e 0.11 mg/L e acido ferulico, preferibilmente in concentrazione compresa tra 60 e 125 mg/L. Una formulazione particolarmente preferita di questo tipo di bevanda, destinata a consumatori donne, comprende: Therefore, if the beverage of the present invention is intended to be used by a female population, it preferably contains, in addition to the aforementioned components, also biotin, preferably in a concentration ranging from 0.07 to 0.11 mg / L and ferulic acid, preferably in a concentration ranging from between 60 and 125 mg / L. A particularly preferred formulation of this type of drink, intended for female consumers, includes:
Epigallocatechina gallato 60 mg/L Epigallocatechin gallate 60 mg / L
L-carnosina 100 mg/L L-carnosine 100 mg / L
acido folico 0.1 mg/L folic acid 0.1 mg / L
Zn<2+>6 mg/L Zn <2+> 6 mg / L
Mg<2+>100 mg/L Mg <2+> 100 mg / L
pirìdossina 1 mg/L pyridoxine 1 mg / L
biotina 0.075 mg/L biotin 0.075 mg / L
7709PTIT Notarbartofo & Gen/asi S.p.A , 7709PTIT Notarbartofo & Gen / asi S.p.A,
acido ferulico 125 mg/L ferulic acid 125 mg / L
tn alternativa, qualora la bevanda della presente invenzione sta destinata ad essere utilizzata da una popolazione maschile questa contiene inoltre K<+>, preferibilmente in forma di potassio citrato, e selenio, preferibilmente in forma di seie nometion ina. Alternatively, if the beverage of the present invention is intended to be used by a male population, it also contains K <+>, preferably in the form of potassium citrate, and selenium, preferably in the form of semenomethion.
Preferibilmente, il K<+>è presente in concentrazione compresa tra 2,5 e 20 mg/L ed il selenio in concentrazione compresa tra 0.02 e 0.05 mg/L. Una formulazione particolarmente preferita di questo tipo di bevanda, destinata a consumatori uomini, comprende: Preferably, the K <+> is present in a concentration ranging from 2.5 to 20 mg / L and selenium in a concentration ranging from 0.02 to 0.05 mg / L. A particularly preferred formulation of this type of drink, intended for male consumers, includes:
Epigallocatechina gallato 60 mg/L Epigallocatechin gallate 60 mg / L
L-carnosina 100 mg/L L-carnosine 100 mg / L
acido folico 0,1 mg/L folic acid 0.1 mg / L
Zn<2+>7,5 mg/L Zn <2+> 7.5 mg / L
Mg<2+>100 mg/L Mg <2+> 100 mg / L
piridossina 1 mg/L pyridoxine 1 mg / L
K<+>2.5 mg/L K <+> 2.5 mg / L
Se 0,02 mg/L If 0.02 mg / L
La bevanda della presente invenzione può contenere inoltre eccipienti per uso alimentare. The beverage of the present invention can also contain excipients for food use.
La Richiedente ha condotto una ricerca su cellule astroglialì ed endoteliali di ratto in cultura, esponendole a varie concentrazioni {10, 50 e 100 μΐ/ml) della suddetta bevanda per 6, 12 e 24 ore. Lo studio ha evidenziato la capacità della bevanda secondo l’invenzione di indurre fortemente, nelle cellule trattate, l'espressione dell’emeossigenasi-l (HO-1), una proteina altamente attiva nella difesa dello stress ossidativo 77Ό9ΡΤΙΤ Notarbartolo & Gen/asi S.p.A. The Applicant has conducted a research on astroglial and endothelial cells of rats in culture, exposing them to various concentrations (10, 50 and 100 μΐ / ml) of the above beverage for 6, 12 and 24 hours. The study highlighted the ability of the drink according to the invention to strongly induce, in the treated cells, the expression of hemeoxygenase-1 (HO-1), a highly active protein in the defense of oxidative stress 77Ό9ΡΤΙΤ Notarbartolo & Gen / asi S.p.A.
(Poon HF, Calabrese V, Scapagnini G, Butterfield DA (2004) J. Gerontoi A Biol Sci Med Sci 59(5): 478-493) e, di conseguenza nel proteggere le cellule dal danno causato da esposizione a radicali liberi, L’emeossigenasi è l'enzima fondamentale per il catabolismo dell’eme, che viene degradato in bìliverdina-bilirubina, monossido di carbonio (CO) e ferro. Questi prodotti sono molecole dall'attività biologica particolarmente significativa: la biliverd ina e la bilirubina, sono dotate di potenti proprietà antiossidanti (Scapagnini G, D'Agata V, Calabrese V, Pascale A, Colombrita C, Alkon D, Cavallaro S, (2002) Brain Res. (Poon HF, Calabrese V, Scapagnini G, Butterfield DA (2004) J. Gerontoi A Biol Sci Med Sci 59 (5): 478-493) and, consequently, in protecting cells from damage caused by exposure to free radicals, L hemeoxygenase is the essential enzyme for the catabolism of heme, which is degraded into biliverdin-bilirubin, carbon monoxide (CO) and iron. These products are molecules with particularly significant biological activity: biliverd ina and bilirubin have powerful antioxidant properties (Scapagnini G, D'Agata V, Calabrese V, Pascale A, Colombrita C, Alkon D, Cavallaro S, (2002 ) Brain Res.
954(1 ):51-59); il CO svolge fondamentali funzioni di segnale e si comporta come un modulatore gassoso delle funzioni vasali (Abraham NG, Scapagnini G, Kappas A. (2003) J Celi Biochem. 90(6); 1098-1111); il ferro è un noto regolatore genico (Smith M A., Wehr K., Harris P. L. R., Siedlak S. L, Connor J. R,, and Perry G. (1998) Brain Res. 788, 232-236), 954 (1): 51-59); CO performs fundamental signal functions and acts as a gaseous modulator of vascular functions (Abraham NG, Scapagnini G, Kappas A. (2003) J Celi Biochem. 90 (6); 1098-1111); iron is a well-known gene regulator (Smith M A., Wehr K., Harris P. L. R., Siedlak S. L, Connor J. R ,, and Perry G. (1998) Brain Res. 788, 232-236),
Oltre a generare molecole attive contro lo stress ossidativo, l’HO-1 diminuisce i livelli di eme che è, di per se, un potente catalizzatore della perossidazione lipidica e della formazione di radicali liberi. Il ruolo svolto datl’HO-1 sul Sistema Nervoso Centrale è attualmente oggetto di intenso studio; la sua attivazione sembra rappresentare un meccanismo di difesa fondamentale per i neuroni esposti al danno ossidativi in situazioni acute, come nell’ictus, o croniche come nell’invecchiamento cerebrale e durante le malattie neurodegenerative quali la malattia di Alzheimer. Difatti, sia il danno ossidativo che i processi infiammatori sono particolarmente elevati nei cervelli dei pazienti affetti da Alzheimer, suggerendo la potenziale 7709PTIT Notarbartolo & Gervasi S.p.A. In addition to generating molecules active against oxidative stress, HO-1 decreases the levels of heme which is, in itself, a powerful catalyst for lipid peroxidation and the formation of free radicals. The role played by HO-1 on the Central Nervous System is currently the subject of intense study; its activation seems to represent a fundamental defense mechanism for neurons exposed to oxidative damage in acute situations, such as in stroke, or in chronic situations such as brain aging and during neurodegenerative diseases such as Alzheimer's disease. In fact, both oxidative damage and inflammatory processes are particularly high in the brains of Alzheimer's patients, suggesting the potential 7709PTIT Notarbartolo & Gervasi S.p.A.
utilità di una terapìa a lungo termine con un composto dotato appunto di potente azione antiossidante e antinfiammatoria. usefulness of a long-term therapy with a compound with a powerful antioxidant and anti-inflammatory action.
Lo studio ha inoltre evidenziato che l'induzione di HO-1 da parte della bevanda dell'invenzione è legata alla sua capacità di attivare un fattore di trascrizione specifico, l’Nrf2. Questo fattore di trascrizione è in grado di indurre fortemente l’espressione di altri vitageni, quali gli enzimi detossificanti di tipo 2, ad alta attività antiossidante e antitumorale. Nelle stesse condizioni sperimentali, inoltre, la bevanda secondo l'invenzione è risultata in grado di attivare notevolmente l’espressione della Hsp70, una heat shock protein coinvolta nella rigenerazione delle proteine danneggiate. The study also highlighted that the induction of HO-1 by the beverage of the invention is linked to its ability to activate a specific transcription factor, Nrf2. This transcription factor is able to strongly induce the expression of other vitagens, such as type 2 detoxifying enzymes, with high antioxidant and antitumor activity. Furthermore, under the same experimental conditions, the drink according to the invention was found to be able to significantly activate the expression of Hsp70, a heat shock protein involved in the regeneration of damaged proteins.
La preparazione della bevanda della presente invenzione ha presentato notevoli difficoltà legate all'instabilità in acqua dei suoi componenti. The preparation of the beverage of the present invention has presented considerable difficulties linked to the instability in water of its components.
E’ quindi un ulteriore aspetto della presente invenzione il procedimento di preparazione di una bevanda atta a rallentare la degenerazione cellulare che accompagna l’invecchiamento, costituita da una soluzione acquosa comprendente epigallocatechìna gallato, L-carnosina, acido folico, Zn<2+>e Mg<2+>, caratterizzato da modalità operative che consentono di solubilizzare le suddette sostanze sensibili evitando o limitando il loro contatto con l'ossigeno, con la luce e con metalli catalizzatori delle reazioni di degradazione. Therefore, a further aspect of the present invention is the process of preparing a beverage suitable for slowing down the cellular degeneration that accompanies aging, consisting of an aqueous solution comprising epigallocatechin gallate, L-carnosine, folic acid, Zn <2+> and Mg <2+>, characterized by operating methods that allow to solubilize the aforementioned sensitive substances avoiding or limiting their contact with oxygen, light and metals catalysts of the degradation reactions.
Riportiamo qui di seguito alcuni esempi di realizzazione della presente invenzione, che non hanno tuttavia carattere limitativo. Here below are some examples of embodiment of the present invention, which, however, are not of a limiting nature.
7709PTIT Notarbariolo & Gervasi 7709PTIT Notarbariolo & Gervasi
ESEMPIO 1 EXAMPLE 1
E’ stata preparata una bevanda costituita da una soluzione acquosa comprendente: A drink was prepared consisting of an aqueous solution comprising:
Epigallocatechina gallato 60 mg/L Epigallocatechin gallate 60 mg / L
L-carnosina 100 mg/L L-carnosine 100 mg / L
acido folico 0.1 mg/L folic acid 0.1 mg / L
Zn<2+>(come citrato) 4 mg/L Zn <2 +> (as citrate) 4 mg / L
Mg<2+>(come gluconato) 100 mg/L Mg <2 +> (as gluconate) 100 mg / L
Acido citrico 1000 mg/L Citric acid 1000 mg / L
Come epigallocatechina gallato è stato utilizzato il prodotto commerciale TEAVIGO<®>(RES PHARMA). The commercial product TEAVIGO <®> (RES PHARMA) was used as epigallocatechin gallate.
La preparazione della suddetta bevanda è stata realizzata secondo le fasi di procedimento di seguito descritte. The preparation of the aforementioned drink was carried out according to the process steps described below.
in dettaglio, si è proceduto alla rimozione dall’acqua delle impurezze dei metalli di transizione, in particolare ferro e rame, mediante opportuno processo e/o utilizzo di un agente chelante. L’acqua così trattata è stata poi posta all'interno di un sistema chiuso ed al riparo dalla luce. Alla soluzione sono stati aggiunti L-carnosina, acido folico, zinco citrato e magnesio gluconato. La miscela è stata agitata fino a completa solubilizzazione di tutti i componenti e successivamente è stato aggiunto acido citrico. Infine, è stato aggiunto l'epigallocatechina gallato e, a solubilizzazione completa, l’acqua è stata sterilizzata mediante microfiltrazione. in detail, the impurities of the transition metals, in particular iron and copper, were removed from the water by means of an appropriate process and / or use of a chelating agent. The water thus treated was then placed inside a closed system and protected from light. L-carnosine, folic acid, zinc citrate and magnesium gluconate were added to the solution. The mixture was stirred until all components were completely dissolved and then citric acid was added. Finally, epigallocatechin gallate was added and, when completely dissolved, the water was sterilized by microfiltration.
7709PTIT Notarbartolo & Servasi S. 7709PTIT Notarbartolo & Servasi S.
ESEMPIO 2 EXAMPLE 2
Utilizzando il procedimento descritto nell’Esempio 1 è stata preparata una bevanda costituita da una soluzione acquosa comprendente: Using the procedure described in Example 1, a drink was prepared consisting of an aqueous solution comprising:
Epigallocatechina gallato 60 mg/L Epigallocatechin gallate 60 mg / L
L-carnosina 100 mg/L L-carnosine 100 mg / L
acido folico 0.1 mg/L folic acid 0.1 mg / L
Zn<2+>(come citrato) 6 mg/L Zn <2 +> (as citrate) 6 mg / L
Mg<2+>(come gluconato) 100 mg/L Mg <2 +> (as gluconate) 100 mg / L
piridossina (come idrocloruro) 1 mg/L pyridoxine (as hydrochloride) 1 mg / L
Biotina 0.075 mg/L Biotin 0.075 mg / L
Acido ferulico 125 mg/L Ferulic acid 125 mg / L
Come epigallocatechina gallato è stato utilizzato il prodotto commerciale TEAViGO<®>(RES PHARMA). The commercial product TEAViGO <®> (RES PHARMA) was used as epigallocatechin gallate.
ESEMPIO 3 EXAMPLE 3
Utilizzando il procedimento descritto nell’Esempio 1 è stata preparata una bevanda costituita da una soluzione acquosa comprendente: Using the procedure described in Example 1, a drink was prepared consisting of an aqueous solution comprising:
Epigallocatechina gallato 60 mg/L Epigallocatechin gallate 60 mg / L
L-carnosina 100 mg/L L-carnosine 100 mg / L
acido folico 0.1 mg/L folic acid 0.1 mg / L
Zn<2+>(come citrato) 7.5 mg/L Zn <2 +> (as citrate) 7.5 mg / L
Mg<2+>(come gluconato) 100 mg/L Mg <2 +> (as gluconate) 100 mg / L
piridossina (come idrocloruro) 1 mg/L pyridoxine (as hydrochloride) 1 mg / L
K<+>(come citrato) 2.5 mg/L K <+> (as citrate) 2.5 mg / L
Se (come selenometionina) 0.02 mg/L If (as selenomethionine) 0.02 mg / L
7709PTIT Notarbartolo & Gervasi S.p.A. Ί 7709PTIT Notarbartolo & Gervasi S.p.A. Ί
Come epigaliocatechina gallato è stato utilizzato il prodotto commerciale TEAVIGO<®>(RES PHARMA). The commercial product TEAVIGO <®> (RES PHARMA) was used as epigaliocatechin gallate.
Claims (15)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001854A ITMI20061854A1 (en) | 2006-09-28 | 2006-09-28 | BEVERAGE SUITED TO SLOW DOWN CELL DEGENERATION THAT ACCOMPANIES AGING |
| PCT/EP2007/060216 WO2008037740A2 (en) | 2006-09-28 | 2007-09-26 | Beverage suitable to retard the cellular degeneration which accompanies ageing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001854A ITMI20061854A1 (en) | 2006-09-28 | 2006-09-28 | BEVERAGE SUITED TO SLOW DOWN CELL DEGENERATION THAT ACCOMPANIES AGING |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITMI20061854A1 true ITMI20061854A1 (en) | 2008-03-29 |
Family
ID=39110862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT001854A ITMI20061854A1 (en) | 2006-09-28 | 2006-09-28 | BEVERAGE SUITED TO SLOW DOWN CELL DEGENERATION THAT ACCOMPANIES AGING |
Country Status (2)
| Country | Link |
|---|---|
| IT (1) | ITMI20061854A1 (en) |
| WO (1) | WO2008037740A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107048383A (en) | 2012-10-04 | 2017-08-18 | 雅培制药有限公司 | For strengthen EGCg to slow down skeletal muscle loss effect method |
| CA2896348C (en) * | 2013-01-28 | 2020-12-08 | Unilever Plc | Skin care compositions comprising folic acid and gallated catechin |
| WO2015191533A1 (en) * | 2014-06-13 | 2015-12-17 | East Carolina University | Methods of using carnosinol and analogs thereof |
| FR3056381B1 (en) * | 2016-09-26 | 2019-11-15 | Futur Optimal | COMPOSITION COMPRISING CARNOSINE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2487588C (en) * | 2002-05-31 | 2011-09-27 | Suomen Ravitsemusinstituutti Oy | Drink composition and a method for composing a drink |
| DE10326822A1 (en) * | 2003-06-11 | 2005-01-05 | Herzpharma Vita-Check Diagnosegeräte GmbH | Dietary supplement, e.g. for increasing general performance, concentration and endurance, comprises NADH, L-carnitine, coenzyme Q10, L-carnosine, succinic acid, ascorbic acid and bioflavonoids |
| WO2005041996A1 (en) * | 2003-10-03 | 2005-05-12 | GREEN MEADOWS RESEARCH, LLC A & L Goodbody | Lotus and methyl donors |
| WO2006026713A2 (en) * | 2004-08-31 | 2006-03-09 | Tracie Martyn International, Llc | Topical benfotiamine and pyridoxamine compositions |
| CA2546464A1 (en) * | 2005-05-04 | 2006-11-04 | Richard Wachsberg | Sequential application of oral and topical formulations for treating wrinkles and other damage to skin |
-
2006
- 2006-09-28 IT IT001854A patent/ITMI20061854A1/en unknown
-
2007
- 2007-09-26 WO PCT/EP2007/060216 patent/WO2008037740A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008037740A3 (en) | 2008-05-15 |
| WO2008037740A2 (en) | 2008-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bjørklund et al. | Oxidative stress in autism spectrum disorder | |
| Cao et al. | Weaning disrupts intestinal antioxidant status, impairs intestinal barrier and mitochondrial function, and triggers mitophagy in piglets | |
| Gil-Mohapel et al. | The role of oxidative stress in Huntington’s disease: are antioxidants good therapeutic candidates? | |
| Romao | Therapeutic value of oral supplementation with melon superoxide dismutase and wheat gliadin combination | |
| Montinaro et al. | Dietary zeolite supplementation reduces oxidative damage and plaque generation in the brain of an Alzheimer's disease mouse model | |
| Ginsburg et al. | Saliva increases the availability of lipophilic polyphenols as antioxidants and enhances their retention in the oral cavity | |
| Walingo | Role of vitamin C (ascorbic acid) on human health-a review | |
| ES2384701T3 (en) | Use of DHA for the treatment of a pathology associated with oxidative cell damage | |
| EP2618832B1 (en) | Composition comprising sod, lutein and zeaxanthin | |
| Walia et al. | Delineation of neuroprotective effects and possible benefits of antioxidantstherapy for the treatment of Alzheimer’s diseases by targeting mitochondrial-derived reactive oxygen species: bench to bedside | |
| WO2005039602A1 (en) | Pharmacologically functional water and use thereof | |
| Aslan et al. | Royal jelly can diminish secondary neuronal damage after experimental spinal cord injury in rabbits | |
| Kim et al. | Anthocyanin extracts from black soybean (Glycine max L.) protect human glial cells against oxygen-glucose deprivation by promoting autophagy | |
| Mock et al. | The influence of vitamins E and C and exercise on brain aging | |
| US20210077514A1 (en) | Nutraceutical Composition for Improving Overall Health | |
| ITMI20061854A1 (en) | BEVERAGE SUITED TO SLOW DOWN CELL DEGENERATION THAT ACCOMPANIES AGING | |
| JP2006008720A (en) | Renal function-improving agent | |
| CN115068629A (en) | Drug-loaded nanoparticle based on curcumin and cerium oxide, and preparation method and application thereof | |
| Hsieh et al. | Effect of taurine in chronic alcoholic patients | |
| Abou Zeid et al. | Normal human copper metabolism | |
| Verma et al. | Emblica officinalis aqueous extract ameliorates ochratoxin-induced lipid peroxidation in the testis of mice | |
| KR102569055B1 (en) | Oral composition comprising beta-escine for reducing acetaldehyde toxicity | |
| US20060134097A1 (en) | Process for production of aqueous colloid of graphite silica particles emitting far-infrared rays | |
| Lin et al. | Antiteratogenic Effects of β‐Carotene in Cultured Mouse Embryos Exposed to Nicotine | |
| US11090274B2 (en) | Formulation and method for supporting retinal health thereby reducing the risk of age-related macular degeneration (AMD) |